Infective Endocarditis: Echocardiographic Assessment

Infective endocarditis (IE) is inflammation of the endocardium, typically involving the surface lining of the heart valves, caused by microbial invasion. Its hallmark finding is the vegetation — an infected mass of platelets, fibrin, and microorganisms — and echocardiography is central to both diagnosis and ongoing management. IE is a serious disease: in-hospital mortality is around 15–20%, with 1-year mortality approaching 40%, and it is considered fatal without appropriate treatment. This tutorial covers diagnosis, echocardiographic findings, and current antibiotic prophylaxis guidance, drawn from the 2020 ACC/AHA and 2025 ESC/EACTS valvular heart disease guidelines.

Etiology

IE is caused by microorganism invasion of the endocardium, usually bacterial. The most frequently implicated organisms include viridans group streptococci and Staphylococcus aureus, though the epidemiology has shifted over time — both guidelines note a recent rise in drug-use-associated IE, and S. aureus IE deserves particular attention because it frequently affects previously normal valves and is seldom accompanied by the classic physical stigmata of endocarditis, making it easy to underdiagnose on clinical grounds alone.

Diagnosis: The Modified Duke Criteria

Both current guidelines are explicit that the Modified Duke Criteria — not echocardiography or blood cultures viewed in isolation — should be used to diagnose IE.

Major criteria:

• Positive blood culture for IE, defined as typical organisms (viridans streptococci, Streptococcus bovis, the HACEK group, S. aureus, or community-acquired enterococci without a primary focus) from two separate cultures, or persistently positive cultures meeting specific timing criteria, or a single positive culture for Coxiella burnetii
• Evidence of endocardial involvement, meaning a positive echocardiogram (an oscillating intracardiac mass on a valve or supporting structure, in the path of a regurgitant jet, or on implanted material, without a better anatomic explanation; an abscess; or new partial dehiscence of a prosthetic valve) or new valvular regurgitation (a worsening or changing existing murmur does not count)

Minor criteria:

• A predisposing heart condition or injection drug use
• Fever above 38°C (100.4°F)
• Vascular phenomena — major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, or Janeway lesions
• Immunological phenomena — glomerulonephritis, Osler’s nodes, Roth’s spots, or rheumatoid factor
• Microbiological evidence not meeting a major criterion, or serological evidence of infection consistent with IE

Classification:

Category	Criteria
Definite IE	Pathological confirmation (organisms or active endocarditis on histology); or 2 major criteria; or 1 major + 3 minor criteria; or 5 minor criteria
Possible IE	1 major + 1 minor criterion; or 3 minor criteria
Rejected	A firm alternative diagnosis; resolution with ≤4 days of antibiotics; no pathological evidence at surgery/autopsy with ≤4 days of antibiotics; or failure to meet the criteria for possible IE

Signs and Symptoms

• Prolonged fever
• A new heart murmur
• Night sweats
• Arthralgia
• Weight loss

Complications

• Valvular leaflet disruption, resulting in regurgitation
• Embolization — pulmonary embolization from right-sided valve vegetations, systemic embolization from left-sided valve vegetations
• Congestive heart failure
• Myocardial or valve ring (paravalvular) abscess — infection extending into the aortic root specifically can produce a mycotic (infectious) aneurysm, part of the broader aortic disease differential
• Peripheral abscess formation, from embolization

Heart failure, paravalvular extension, and embolic events are the three most frequent and most severe complications of IE — they are also the three leading indications for early surgery, which is ultimately performed in roughly half of all IE cases.

Diagnostic Testing Beyond Echocardiography

ECG — new conduction abnormalities (particularly a new or worsening atrioventricular block) may suggest perivalvular extension of infection, such as an abscess tracking into the conduction system.

Echocardiographic Findings

M-Mode

• Mitral valve — thickened, smudged, or “shaggy”-appearing leaflets
• Aortic valve — thickening and fine fluttering of the leaflets; linear or nonuniform echoes in the LVOT suggesting vegetations or a flail leaflet
• Severe acute aortic regurgitation (from valve destruction) — premature mitral valve closure and premature aortic valve opening, the same signs described in the Aortic Regurgitation tutorial for acute severe AR from any cause

2D Echocardiography

• Vegetations — typically located on the upstream side of the leaflet relative to normal forward flow (the atrial side of the mitral and tricuspid valves, the ventricular side of the aortic and pulmonic valves), consistent with where the regurgitant/turbulent flow strikes the leaflet — see Approach to Cardiac Masses for how this same attachment-side logic distinguishes a vegetation from a papillary fibroelastoma, which characteristically attaches to the opposite, downstream side
• Chamber enlargement, often secondary to significant regurgitation
• Flail leaflets — best visualized on 2D imaging
• Valve ring (paravalvular) abscess — an echo-free cavity within the annulus or adjacent structures (the septum or aortic root); aortoseptal discontinuity can result when an abscess cavity disrupts the normal fibrous continuity between the aortic root and septum
• Purulent pericarditis with effusion — a less common but recognized complication when infection extends beyond the valve annulus into the pericardial space; see Pericardial Effusion for how an echogenic or organized effusion is distinguished from simple fluid, and Cardiac Tamponade if it progresses to hemodynamic compromise

Doppler

• Assess the presence and severity of any resulting regurgitation
• In severe acute aortic regurgitation, PW Doppler at the mitral leaflet tips shows a shortened deceleration time (< 150 ms) with an increased E/A ratio — reflecting rapidly rising LV diastolic pressure, as covered in more detail in the Aortic Regurgitation tutorial
• Abnormal continuous flow at a suspicious site can suggest an abscess cavity communicating with a cardiac chamber

TTE vs. TEE

• TTE sensitivity for vegetations is roughly 50–90% in native valve endocarditis, but only about 36–69% in prosthetic valve endocarditis — specificity remains high (>90%) throughout. TTE also retains real value even when a vegetation isn’t well seen: it assesses ventricular size and function, estimates pulmonary pressures, and images the anterior aspect of a prosthetic aortic valve better than TEE typically can.
• TEE sensitivity is substantially higher, roughly 90–100% for native valve endocarditis, and is superior to TTE for detecting paravalvular complications specifically (abscess, fistula, pseudoaneurysm, valve perforation) — see Transesophageal Echocardiography for the standard views used to interrogate the aortic root and perivalvular tissue for abscess.
• TEE is recommended whenever TTE is nondiagnostic, when a complication is suspected or has developed clinically, or when intracardiac device leads are present. It is also particularly valuable when S. aureus bacteremia is present without an identified source, given how often S. aureus IE lacks classic clinical findings.
• A single negative TEE does not rule out IE. If clinical suspicion of persistent infection remains, or complications develop, the study should be repeated — early paravalvular abscesses in particular can be missed on an initial study and only become recognizable as nonspecific thickening evolves into a clearer cavity over subsequent days.

Important Notes on Vegetation Assessment

• Vegetations smaller than roughly 3 mm may not be detectable on TTE. The absence of a visible vegetation does not rule out IE — diagnosis still relies on the full Duke Criteria framework, not imaging alone.
• A mobile vegetation greater than 10 mm in length is a recognized risk factor for embolic events, and in native left-sided valve endocarditis, may itself be considered as supporting early surgery even without other indications, particularly when combined with other high-risk features.
• Increasing vegetation size on therapy should be regarded as a risk factor for a new embolic event; a stable or shrinking vegetation on treatment is reassuring but can be harder to interpret definitively.
• IE frequently occurs on valves with pre-existing structural disease — mitral valve prolapse and bicuspid aortic valve are both well-recognized predisposing substrates.

Antibiotic Prophylaxis: A Much Narrower List Than Older Teaching Suggests

This is worth stating plainly, since older teaching materials — including risk-stratified “high/intermediate/low risk” frameworks covering a broad range of valve conditions — have been superseded. Both the 2020 ACC/AHA and 2025 ESC/EACTS guidelines confirm the same, much narrower set of indications for antibiotic prophylaxis, and only before specific dental procedures — those involving manipulation of gingival tissue, the periapical region of teeth, or perforation of the oral mucosa:

• Prosthetic cardiac valves, including transcatheter-implanted prostheses and homografts
• Prosthetic material used for valve repair, such as annuloplasty rings, chords, or clips — including after transcatheter mitral or tricuspid valve repair
• Previous IE
• Unrepaired cyanotic congenital heart disease, or repaired congenital heart disease with residual shunts or valvular regurgitation at or adjacent to a prosthetic patch or device
• Cardiac transplant recipients with valve regurgitation attributable to a structurally abnormal valve

Conditions not on this list — including mitral valve prolapse, pure mitral stenosis, tricuspid or pulmonary valve disease, bicuspid aortic valve, hypertrophic cardiomyopathy, and most unrepaired non-cyanotic congenital lesions — do not warrant antibiotic prophylaxis under current guidance, even though many of these same conditions carry some elevated underlying risk of developing IE. That’s an important distinction: a condition that raises someone’s baseline susceptibility to IE is not automatically an indication for prophylactic antibiotics before a procedure — the evidence for prophylaxis specifically has only ever supported this narrower group. ACC/AHA is also explicit that antibiotic prophylaxis is not recommended for nondental procedures (such as TEE, upper endoscopy, colonoscopy, or cystoscopy) in the absence of active infection, and that there is no evidence supporting prophylaxis for gastrointestinal or genitourinary procedures absent known infection.

This narrower approach reflects a genuine evolution in evidence: no randomized controlled trial has definitively established that antibiotic prophylaxis prevents IE, and indiscriminate antibiotic use carries its own real costs — antimicrobial resistance, Clostridium difficile colitis, and drug toxicity among them. The current guidelines represent a deliberate narrowing to the patients judged to be at both the highest risk of developing IE and the highest risk of a poor outcome if they do.

A note on sourcing: the specific criterion of an aortic root wall thickness greater than 9 mm supporting an abscess diagnosis is standard echocardiography teaching, but wasn’t independently located as a stated figure in either guideline reviewed for this page.